What happened with DCGO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
DocGo’s Ambulnz business takes patients between healthcare facilities and to appointments, including dialysis, in the United States and United Kingdom. It provides emergency and non-emergency ambulance services and wheelchair transport, billing insurers, government healthcare programs and healthcare facilities. This business supplies most of DocGo’s revenue. Its dispatch technology coordinates trips, while ShareLink lets patients and partners see vehicle locations and expected arrival times.
Its other main business brings clinicians to homes, workplaces and other locations, sometimes pairing on-site staff with remote practitioners. Municipalities, health systems, health plans and employers pay for these services. For health-plan partners such as Elevance Health and Molina, DocGo engages hard-to-reach patients and helps them receive care they have missed. Payment arrangements that would share financial risk with health plans remain plans rather than established terms.
Government contracts remain a substantial revenue source, and one customer—a public benefit corporation serving municipal agencies—accounts for a large share of revenue. Its project contracts can be terminated at will on short notice. DocGo has finished winding down its New York migrant-related programs, which included shelter and security as well as medical care, and says government work is no longer central to its growth strategy.
The business depends on keeping enough qualified clinical staff and collecting payment for services already delivered. Providers must obtain relevant program enrollment before receiving Medicare or Medicaid reimbursement. State laws also limit corporate involvement in medical practice, including employment of physicians and control over clinical decisions.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
As migrant-related government work winds down, DocGo now depends chiefly on medical-transport trip volumes and reimbursement, making its named transportation rival Modivcare an important comparison missing from this list.
Teladoc Health, Inc. competes with DocGo to sell virtual clinical care and chronic-condition support to health plans, employers and healthcare providers. Its business-focused Integrated Care segment is the closer comparison, rather than its consumer-focused BetterHelp counseling business.
Elevance Health, Inc. pays DocGo to help health-plan members engage with care and receive missing recommended services. Elevance earns premiums and employer administration fees; expansion of its DocGo programs into new geographies is the development to watch for DocGo.
Molina Healthcare, Inc. is a paying customer for DocGo’s services that help members of government-sponsored insurance programs receive missing care. Molina collects premiums to arrange and pay for members’ healthcare; Medicaid supplied 75% of its consolidated premium revenue in 2025, making that member group especially relevant to this relationship.
Option Care Health, Inc. competes with DocGo for parts of insurer- and government-funded care in patients’ homes, but specializes in giving medicines by infusion. Its contracts with health plans and other payers for those medicines and services are the relevant comparison, not DocGo’s broader mobile-care offering.
The Pennant Group, Inc. overlaps with DocGo in providing nursing and other clinical care in patients’ homes, paid for by managed-care plans and government programs. Pennant’s home-health services, including nursing and physical therapy, are the closer comparison than its senior-living business.
Omada Health, Inc. competes with DocGo to sell health plans technology-supported chronic-condition care and patient engagement outside traditional clinics. Omada’s virtual diabetes and hypertension programs, funded by organizations covering eligible members’ care, are the concrete overlap with DocGo’s chronic-patient monitoring and engagement work.
Molina Healthcare, Inc. earningsMOH
Molina Healthcare’s report will show how changes in its Medicaid business affect a customer that pays DocGo to help members receive missing care.
Look at Molina Healthcare’s Medicaid membership alongside premium revenue from that business. Stable membership and premiums would indicate that this government-insurance customer channel retains covered people and funding; a marked contraction would weaken that support for DocGo’s services to these members. Molina’s results would not, by themselves, establish whether it buys more or less from DocGo.
Option Care Health, Inc. earningsOPCH
Option Care Health’s report will show whether health plans and other payers are supporting home-infusion care, a specialized part of the home-based market that overlaps with DocGo.
Read Option Care Health’s home-infusion revenue and service volume alongside its comments on payer demand. Growth in both would show that payers continue to fund this type of home treatment, offering one sign of support in a market DocGo also serves; declines would indicate pressure in this service line, not prove that demand for DocGo’s broader mobile care is falling.
DocGo Inc. earningsThis company
DocGo’s report will show whether ambulance transportation can offset falling mobile-health revenue and ease pressure on cash.
Read transportation revenue alongside trip volume and average price per trip, then compare them with mobile-health revenue and operating cash flow. More trips with stable pricing, a smaller mobile-health decline and better cash generation would show transportation is taking up more of the business while easing operating pressure. Weaker transportation or pricing, continued steep mobile-health declines and deteriorating cash flow would show the shift has not filled the gap.
